Last reviewed · How we verify
BRII-196/BRII-198
BRII-196/BRII-198 is a combination of two monoclonal antibodies that neutralize SARS-CoV-2 spike protein to prevent and treat COVID-19 infection.
BRII-196/BRII-198 is a combination of two monoclonal antibodies that neutralize SARS-CoV-2 spike protein to prevent and treat COVID-19 infection. Used for Post-exposure prophylaxis of COVID-19, Early treatment of mild-to-moderate COVID-19.
At a glance
| Generic name | BRII-196/BRII-198 |
|---|---|
| Sponsor | National Institute of Allergy and Infectious Diseases (NIAID) |
| Drug class | Monoclonal antibody combination |
| Target | SARS-CoV-2 spike protein receptor-binding domain |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
BRII-196 and BRII-198 are individually engineered monoclonal antibodies designed to bind non-overlapping epitopes on the SARS-CoV-2 spike protein receptor-binding domain, preventing viral attachment to human ACE2 receptors. The combination approach is intended to reduce the risk of viral escape and resistance. This dual-antibody cocktail can be used for both post-exposure prophylaxis and early treatment of COVID-19.
Approved indications
- Post-exposure prophylaxis of COVID-19
- Early treatment of mild-to-moderate COVID-19
Common side effects
- Infusion-related reactions
- Hypersensitivity reactions
- Injection site reactions
Key clinical trials
- ACTIV-2: A Study for Outpatients With COVID-19 (PHASE2, PHASE3)
- BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) (PHASE3)
- ACTIV-3: Therapeutics for Inpatients With COVID-19 (PHASE3)
- SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine (PHASE4)
- A Phase 1 Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 (PHASE1)
- A Safety and Efficacy Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 for the Treatment of Patients With COVID-19 (PHASE2)
- A Study of Human Monoclonal Antibodies, BRII-196 and BRII-198 (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BRII-196/BRII-198 CI brief — competitive landscape report
- BRII-196/BRII-198 updates RSS · CI watch RSS
- National Institute of Allergy and Infectious Diseases (NIAID) portfolio CI